A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors

Overview of attention for article published in Investigational New Drugs, September 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#12 of 1,266)
High Attention Score compared to outputs of the same age (95th percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news: 7 news outlets

twitter: 2 X users

Citations

dimensions_citation: 53 Dimensions

Readers on

mendeley: 65 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 1,437 followers.

RT @DDNewsOnline: OncoMed notes #tumor shrinkage & partial responses in Ph1a #clinicaltrial of navicixizumab vs refractory solid #tumors #…

06 Dec 2018

Reply Repost Favourite

A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors. https://t.co/UZmQnQKkdv

20 Sep 2018

Reply Repost Favourite